盐酸去甲维拉帕米
盐酸去甲维拉帕米 性质
| 熔点 | softens at 50°C, 155-160°C dec. |
|---|---|
| 闪点 | 9℃ |
| 储存条件 | desiccated |
| 溶解度 | H2O: >10 mg/mL |
| 形态 | 固体 |
| 颜色 | 白色 |
| 稳定性 | 吸湿性 |
| EPA化学物质信息 | Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, hydrochloride (1:1) (67812-42-4) |
盐酸去甲维拉帕米 用途与合成方法
Calcium channel blocker
P-glycoprotein (P-gp) inhibitor
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride) is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil.
Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic.
Norverapamil hydrochloride (9 mg/kg; p.o.), a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng▪h/ml, and 41.6 ng/mL, respectively.
| Animal Model: | Male Sprague-Dawley rats |
| Dosage: | 9 mg/kg (Pharmacokinetic Study) |
| Administration: | Oral administration |
| Result: | t 1/2 =9.4 hours; AUC=260 ng▪h/mL; C max =41.6 ng/mL. |
盐酸去甲维拉帕米 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-100750 | 1 mg | 400 | ||
| 2024-11-08 | HY-100750 | 盐酸去甲维拉帕米 | 67812-42-4 | 5mg | 1400 |
